(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 5% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.78%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.69%.
Abbvie's revenue in 2024 is $54,318,000,000.On average, 9 Wall Street analysts forecast ABBV's revenue for 2024 to be $96,266,525,318,602, with the lowest ABBV revenue forecast at $95,765,820,211,467, and the highest ABBV revenue forecast at $97,042,371,016,715. On average, 9 Wall Street analysts forecast ABBV's revenue for 2025 to be $103,277,698,709,360, with the lowest ABBV revenue forecast at $100,567,094,801,229, and the highest ABBV revenue forecast at $105,555,615,567,045.
In 2026, ABBV is forecast to generate $111,215,869,624,141 in revenue, with the lowest revenue forecast at $106,369,959,785,544 and the highest revenue forecast at $115,372,014,011,410.